Mild to moderate atopic dermatitis
Conditions
Brief summary
The primary endpoint of the study is the percent change from baseline (Visit 1) to Visit 4 (EOT) assessed by Eczema Area and Severity Index (EASI)
Detailed description
Percent change of Eczema Area and Severity Index (EASI) between visits, Percent change of the total affected body surface area (BSA) between visits, and between baseline and week 3 (EOT), Change of the Investigator’s Global Assessment (IGA) between visits, and between baseline and week 3 (EOT), Evaluation of Overall Therapeutic Success by the investigator and patient at week 3 (EOT), Patient´s assessment of severity of pruritus
Interventions
DRUGVehicle to Methylprednisolone Aceponate Ointment
DRUGMethylprednisolone Aceponate Ointment
DRUGAdvantan® 0
DRUG1% Salbe
Sponsors
Dermapharm AG
Eligibility
Sex/Gender
All
Age
0 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is the percent change from baseline (Visit 1) to Visit 4 (EOT) assessed by Eczema Area and Severity Index (EASI) | — |
Secondary
| Measure | Time frame |
|---|---|
| Percent change of Eczema Area and Severity Index (EASI) between visits, Percent change of the total affected body surface area (BSA) between visits, and between baseline and week 3 (EOT), Change of the Investigator’s Global Assessment (IGA) between visits, and between baseline and week 3 (EOT), Evaluation of Overall Therapeutic Success by the investigator and patient at week 3 (EOT), Patient´s assessment of severity of pruritus | — |
Countries
Germany
Outcome results
None listed